Pages
Products
AAV9-CAG-GCaMP6f

AAV9-CAG-GCaMP6f

Cat.No. :  AAV00279Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00279Z
Description AAV serotype 9 particles contain calcium indicator GCaMP6f under CAG promoter.
Serotype AAV Serotype 9
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Currently, more than 800 gene and cell medicines are in various stages of clinical development pipelines for a range of diseases. The recent success of gene and cell therapies is largely due to efficient gene delivery - either directly to the patient (in vivo) or to cells isolated from the patient that are manipulated for use in cell therapies (in vitro). Viral vector platforms are central to the development of gene and cell therapies. Most viral vectors used in gene and cell therapies can be divided into two categories: predominantly integrating and predominantly non-integrating vectors. For ex vivo cell therapies, integrating vectors are used for gene delivery, while AAV vectors are the most widely used gene delivery vectors for in vivo gene therapies. AAV2 is used in a variety of gene therapies due to its various desirable properties, including induction of gene expression for more than 10 months in vivo. However, after systemic administration of AAV2, vascular cell transfection efficiency was low, with a large amount of virus located in the liver and spleen. When AAV2 was compared to other serotypes, it was observed that the AAV1, AAV6, AAV8, and AAV9 serotypes more efficiently crossed the endothelial barrier after intravascular injection and more effectively targeted organ gene expression. Among these novel AAV serotypes, AAV serotype 9 (AAV9) has been identified as an attractive vector due to its superior performance in muscle, heart, and lung transduction.

The auditory striatum is a sensory part of the dorsal striatum that plays a crucial role in learning and memory. However, in contrast to its role and underlying mechanisms in operant conditioning, little is known about its contribution to classical auditory fear conditioning. Here, researchers reveal the role of the auditory striatum in auditory-conditioned fear memory. They found that optogenetic inhibition of auditory striatal neurons impaired fear memory formation, which was mediated through the striatum-amygdala pathway. Using calcium imaging in behaving mice, researchers found that the responses of auditory striatal neurons to conditioned tones were enhanced during memory acquisition and expression. Furthermore, nigrostriatal dopaminergic projections play an important role in mediating conditioning-induced striatal enhancement. Together, these findings demonstrate the existence of a nigrostriatal-amygdala circuit for conditioned fear memory formation and expression.

Here, researchers injected AAV9-CAG-GCaMP6f into the auditory striatum and implanted a GRIN lens above the injection site (Figure 1a). Researchers allowed the virus to incubate and express for at least 3 weeks before implanting the baseplate. Seven days after baseplate implantation, mice were habituated to the camera mount for 4 days before auditory fear conditioning. GCaMP6f signals from auditory striatal neurons were recorded during each task session. In collected images, regions of interest (ROI) were detected by CNMF-E and registered using the CellReg function, which facilitated the recording of auditory striatal neurons throughout habituation, conditioning, and probe sessions (Figure 1b). Recordings from each neuronal ROI were aligned to the onset of the conditioning tone and sorted based on the amplitude of the tone response within a 1-second time window. The peak Z-score, which represents the change in fluorescence in response to the tone, was measured and plotted for each task session (Figure 1c, top). The number of neurons whose activity increased, decreased, or remained unchanged in response to the tone was quantified (Figure 1c, bottom). The number of neurons with increased responses to the conditioning tone increased significantly during the conditioning and first probe sessions (Figure 1d). Interestingly, tone responses increased gradually and significantly during the conditioning sessions for the eight conditioning tones (Figure 1e).

Auditory fear conditioning potentiates conditioned tone-induced activity in the auditory striatum.Figure 1. Auditory fear conditioning potentiates conditioned tone-induced activity in the auditory striatum. (Chen A P F, et al., 2023)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Highly recommend

This AAV9-CAG-GCaMP6f significantly simplified our experimental workflow, saving time and resources while ensuring precise and effective results. Highly recommend it for any lab focused on neuronal imaging!

United States

07/10/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction